Transforming Outcomes in AL Amyloidosis with Precision Medicine and Targeted Therapies

Heather Landau, MD, initiates a discussion on the landscape of AL amyloidosis, offering insights into the definition and characteristics of this rare disease.

Vaishali Sanchorawala, MD, examines the signs and symptoms linked to AL amyloidosis, underscoring that distinctive symptoms may not manifest in patients until later stages of the disease, potentially causing delays in diagnosis.

A panel of oncology experts offer insights into the diagnosis of AL amyloidosis, emphasizing the difficulties associated with early detection.

Jeffrey Zonder, MD, offers an overview of the current treatment landscape for AL amyloidosis.

A panel of expert oncologists examine current unmet needs in the treatment landscape for AL amyloidosis.

Jeffrey Zonder, MD, provides an overview of treatment strategies using monoclonal antibodies for the treatment of AL amyloidosis.

Faculty share insights into the treatment strategies using CD38-directed monoclonal antibodies (mAbs) in patients with AL amyloidosis.

Faculty delve into potential challenges related to the management of patients with AL amyloidosis and cardiac involvement, discussing the associated prognostic implications.

A panel of expert oncologists discuss the importance of cardiac staging for patients with AL amyloidosis and its role in guiding overall treatment.

A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.

A panel of expert oncologists explore the ongoing AFFIRM-AL trial, examining birtamimab in patients with a diagnosis of Mayo stage IV AL amyloidosis.

Vaishali Sanchorawala, MD, provides insights on the pooled safety analysis of data from phase 1 to 3 trials, including PRONTO and VITAL, which investigated the use of birtamimab in patients with light chain (AL) amyloidosis.

A panel of expert oncologists discuss the underlying rationale and potential role for CAR T therapy in patients with AL amyloidosis.

Faculty offer insights on the NEXICART-1 phase 1 clinical trial investigating the safety and efficacy of NXC-201 in patients with AL amyloidosis and discuss potential clinical implications on the study’s findings.

Heather Landau, MD, invites panelists to provide their insights on the future outlook for the treatment of AL amyloidosis.